Efficacy of CBRT as an adjuvant to Entecavir for hepatitis B complicated with liver fibrosis

Summaries 3 min 456

Font Size

Created On: 14/11/2022

A systematic review and meta-analysis of randomized controlled trials (RCTs) examined the effectiveness and safety of Compound Biejia-Ruangan tablet (CBRT) as an additional modality to Entecavir for the treatment of hepatitis B infection complicated with liver fibrosis.

See All

Key take away

For treatment of chronic hepatitis B infection complicated with hepatic fibrosis, compound Biejia-Ruangan tablet as an add-on treatment to Entecavir was superior to entecavir monotherapy, with fewer adverse events.

Background

Method

Databases including the Wangfang, CBM, VIP, CNKI, Embase, Cochrane Library, and PubMed were explored for relevant trials. The major endpoints were biochemical characteristics of type IV collagen, pretype-III collagen, laminin, and serum hyaluronic acid. The total effect rate, the frequency of adverse events, and the liver function indicators of serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin levels were the secondary endpoints ascertained. Study selection, extraction of data, and quality evaluation were conducted. Statistical analysis was conducted with RevMan 5.3 software.

Result

Overall, eight RCTs with 747 volunteers were incorporated. CBRT, used as an adjunct to Entecavir, had a more positive impact on serum levels of hyaluronic acid (mean difference [MD] = -28.15), laminin (MD = -29.46), pretype-III collagen (MD = -11.83), and type IV collagen (MD = -19.62); ALT (MD = -16.83), AST (MD = -20.52), and total bilirubin (MD = -7.54); and total effect rate (odds ratio = 3.53). Additionally, CBRT as an additional therapy to Entecavir had a lower incidence rate of adverse events (odds ratio = 0.54) than Entecavir monotherapy.

Conclusion

CBRT, when used as an adjunct to Entecavir, may benefit patients with hepatitis B complicated with liver fibrosis.

Source:

Medicine (Baltimore)

Link:

https://pubmed.ncbi.nlm.nih.gov/35960113/

Article:

Compound Biejia-Ruangan tablet as an adjunctive therapy to Entecavir for chronic hepatitis B complicated with hepatic fibrosis: A systematic review and meta-analysis of randomized controlled trials